Moreno, V., Hernandez, T., Melero, I., Sanmamed, M., Spanggaard, I., Rohrberg, K. S., Tabernero, J., Azaro, A., Garcia, M. M., Rodriguez-Vida, A., Claus, C., Heil, F., Krieter, O., Grimm, O., Canamero, M., Duarte, J., Nica, A., Davydov, I., Hettich, M., Ooi, C., Heichinger, C., Guarin, E., Helbaj, R., Tanos, T., Nueesch, E., Ceppi, M., Moreno, I., & Calvo, E. (n.d.). 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors. Journal for immunotherapy of cancer, 8, A225–A226. http://access.bl.uk/ark:/81055/vdc_100144729544.0x000004